Advertisement
IONS or REGN or VRTX
Which Stock Would AI Choose? Ionis Pharmaceuticals (IONS) vs. Regeneron Pharmaceuticals (REGN) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- IONS leads YTD performance at +8.57%, driven by FDA priority review for olezarsen and strong Q4 revenue growth, contrasting with more stable but lower returns from peers.
- REGN offers market cap stability at $80B with YTD +1.54% and 1-year +12.50%, bolstered by Dupixent demand and obesity trial successes amid sector volatility.
- VRTX commands the largest market cap at $117B, with YTD +2.01%, supported by cystic fibrosis franchise expansion into pain and kidney therapies.
- All three biotech leaders show robust 52-week ranges, with IONS delivering exceptional 1-year gains of +110.87% on pipeline catalysts.
- Recent momentum favors IONS due to regulatory wins, while REGN and VRTX emphasize diversified revenue streams.
- Biotech sector exposure highlights trade-offs: high-growth RNA and rare disease focus for IONS versus established blockbusters at REGN and VRTX.
Introduction
This stock comparison examines IONS, REGN, and VRTX, three prominent biotech firms specializing in innovative therapies for serious diseases. Investors and traders tracking the biotechnology sector may find value in analyzing their relative performance, as these companies navigate pipeline advancements, regulatory milestones, and market sentiment shifts. With distinct focuses—RNA-targeted medicines for IONS, monoclonal antibodies and collaborations for REGN, and cystic fibrosis dominance expanding for VRTX—this overview highlights key contrasts in recent market positioning and growth drivers amid evolving healthcare demands.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS), a commercial-stage biotechnology company headquartered in Carlsbad, California, pioneers RNA-targeted medicines for rare diseases. Its portfolio includes TRYNGOLZA for familial chylomicronemia syndrome, DAWNZERA for hereditary angioedema, and WAINUA for ATTRv-PN, alongside a robust Phase 3 pipeline like olezarsen for severe hypertriglyceridemia.
In recent market activity, IONS shares trade around $72, with a 52-week range of $23.95–$86.74 and market cap of $11.95B. YTD performance stands at +8.57%, outpacing peers, fueled by Q4 2025 revenue of $203M (up 34% YoY) and FDA acceptance of olezarsen sNDA on priority review with a June 30 PDUFA date. New DAWNZERA data presentations and analyst price target upgrades to $103 have boosted sentiment, reflecting optimism around independent launches and rare disease franchise expansion despite broader biotech pressures.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN), based in Tarrytown, New York, develops therapies for eye diseases, inflammation, cancer, and more, with key products like EYLEA for macular degeneration, Dupixent for atopic dermatitis, and Libtayo for skin cancer. Collaborations with Bayer and Sanofi enhance its diversified portfolio.
Recent weeks show REGN shares near $759, within a 52-week range of $476.49–$821.11, and $80.25B market cap. YTD return is +1.54%, with 1-year at +12.50%, supported by Q4 2025 revenue of $3.88B and strong Dupixent uptake offsetting EYLEA competition. Positive Phase 3 obesity trial results and an expanded Illumina alliance for genomics have sustained steady momentum, though minor fluctuations reflect sector headwinds and valuation debates.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals (VRTX), headquartered in Boston, Massachusetts, leads in cystic fibrosis treatments with TRIKAFTA, KAFTRIO, and emerging therapies like CASGEVY for sickle cell disease, JOURNAVX for acute pain, and inaxaplin for kidney disease.
VRTX shares hover at $462, with a 52-week range of $362.50–$515.67 and $117.47B market cap. YTD performance is +2.01%, driven by Q4 2025 revenue of $3.19B (up 9.5% YoY), though EPS slightly missed estimates. Data sharpening focus on kidney and pain revenue potential, alongside CF portfolio growth, have influenced positive sentiment, tempered by recent dips amid industry trends.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from hundreds of bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—including technical analysis, fundamental insights, and varying timeframes like 5min, 15min, or 60min—tailored to current market conditions such as volatility levels (low, medium, high). Out of 351 total AI robots, 25 trending ones are highlighted as Signal Agents (real-time copy trading signals without balance minimums), Virtual Agents (with risk management), and Brokerage Agents (from Tickeron's accounts). Past performances have shown annualized returns up to 279% in select sectors, with win rates reaching 90% on leveraged ETFs, underscoring their adaptability. Traders interested in biotech like IONS, REGN, or VRTX can explore these bots for potential edges. Visit Trending AI Robots to review and copy top performers suited to today's environment.
Head-to-Head Comparison
IONS, REGN, and VRTX operate in biotech but diverge in business models: IONS emphasizes RNA-targeting for rare diseases with partnership revenue, while REGN leverages monoclonal antibodies and collaborations like Dupixent for broader inflammatory indications, and VRTX focuses on CF modulators expanding to gene therapies and pain.
Growth drivers contrast IONS' regulatory catalysts (e.g., olezarsen priority review) against REGN's blockbuster stability and VRTX's CF dominance. Recent momentum favors IONS (+8.57% YTD), over VRTX (+2.01%) and REGN (+1.54%). Risk factors include pipeline dependency for IONS, competition for REGN's EYLEA, and expansion uncertainties for VRTX. Valuation sensitivity is highest for smaller-cap IONS, with market sentiment tilting toward its upside potential versus peers' scale.
Tickeron AI Verdict
Tickeron’s AI currently favors IONS based on superior trend consistency, YTD outperformance, and near-term catalysts like olezarsen’s priority review, positioning it for relative strength amid biotech volatility. While VRTX offers scale and REGN stability, IONS’ momentum suggests a higher probability of near-term gains.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IONS’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 2 green FA rating(s), and VRTX’s FA Score reflects 0 green FA rating(s).
- IONS’s FA Score: 0 green, 5 red.
- REGN’s FA Score: 2 green, 3 red.
- VRTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IONS’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 2 bullish TA indicator(s), and VRTX’s TA Score reflects 4 bullish TA indicator(s).
- IONS’s TA Score: 4 bullish, 4 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
- VRTX’s TA Score: 4 bullish, 4 bearish.
Price Growth
IONS (@Biotechnology) experienced а +0.72% price change this week, while REGN (@Biotechnology) price change was +0.23% , and VRTX (@Biotechnology) price fluctuated +1.13% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
IONS is expected to report earnings on Apr 29, 2026.
REGN is expected to report earnings on Apr 29, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| IONS | REGN | VRTX | |
| Capitalization | 12.5B | 79.4B | 112B |
| EBITDA | -273.12M | 5.82B | 4.87B |
| Gain YTD | -4.298 | -2.643 | -2.682 |
| P/E Ratio | N/A | 18.09 | 28.80 |
| Revenue | 944M | 14.3B | 12B |
| Total Cash | 2.68B | 8.61B | 6.61B |
| Total Debt | 2.07B | 2.71B | 2.03B |
IONS | REGN | VRTX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 63 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 3 Undervalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 62 | 75 | 35 | |
SMR RATING 1..100 | 98 | 54 | 40 | |
PRICE GROWTH RATING 1..100 | 41 | 26 | 59 | |
P/E GROWTH RATING 1..100 | 74 | 40 | 53 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for VRTX (80) and is significantly better than the same rating for IONS (100). This means that REGN's stock grew significantly faster than VRTX’s and significantly faster than IONS’s over the last 12 months.
VRTX's Profit vs Risk Rating (35) in the Biotechnology industry is in the same range as IONS (62) and is somewhat better than the same rating for REGN (75). This means that VRTX's stock grew similarly to IONS’s and somewhat faster than REGN’s over the last 12 months.
VRTX's SMR Rating (40) in the Biotechnology industry is in the same range as REGN (54) and is somewhat better than the same rating for IONS (98). This means that VRTX's stock grew similarly to REGN’s and somewhat faster than IONS’s over the last 12 months.
REGN's Price Growth Rating (26) in the Biotechnology industry is in the same range as IONS (41) and is somewhat better than the same rating for VRTX (59). This means that REGN's stock grew similarly to IONS’s and somewhat faster than VRTX’s over the last 12 months.
REGN's P/E Growth Rating (40) in the Biotechnology industry is in the same range as VRTX (53) and is somewhat better than the same rating for IONS (74). This means that REGN's stock grew similarly to VRTX’s and somewhat faster than IONS’s over the last 12 months.
| IONS | REGN | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 80% | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 75% | 3 days ago 75% | 3 days ago 64% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 52% | 3 days ago 64% |
| MACD ODDS (%) | 3 days ago 73% | 3 days ago 49% | 3 days ago 62% |
| TrendWeek ODDS (%) | 3 days ago 71% | 3 days ago 66% | 3 days ago 62% |
| TrendMonth ODDS (%) | 3 days ago 74% | 3 days ago 60% | 3 days ago 36% |
| Advances ODDS (%) | 5 days ago 66% | 19 days ago 64% | 6 days ago 63% |
| Declines ODDS (%) | 7 days ago 65% | 4 days ago 51% | 4 days ago 43% |
| BollingerBands ODDS (%) | 3 days ago 67% | 3 days ago 49% | N/A |
| Aroon ODDS (%) | 3 days ago 74% | 3 days ago 70% | 3 days ago 30% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GOEX | 93.42 | 2.34 | +2.57% |
| Global X Gold Explorers ETF | |||
| VHT | 278.45 | 4.16 | +1.52% |
| Vanguard Health Care ETF | |||
| BOE | 11.77 | 0.06 | +0.51% |
| BlackRock Enhanced Global Dividend Trust | |||
| PMIO | 50.98 | 0.17 | +0.32% |
| PGIM Municipal Income Opportunities ETF | |||
| AMZD | 9.12 | -0.01 | -0.13% |
| Direxion Daily AMZN Bear 1X ETF | |||
IONS and
Correlation & Price change
A.I.dvisor indicates that over the last year, IONS has been closely correlated with CYTK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if IONS jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | +0.60% | ||
| CYTK - IONS | 66% Closely correlated | +1.97% | ||
| MLYS - IONS | 66% Loosely correlated | +0.07% | ||
| MNKD - IONS | 49% Loosely correlated | +3.27% | ||
| IDYA - IONS | 47% Loosely correlated | +4.31% | ||
| ARWR - IONS | 46% Loosely correlated | +2.25% | ||
More | ||||
VRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with CRSP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | +1.27% | ||
| CRSP - VRTX | 37% Loosely correlated | +4.07% | ||
| EDIT - VRTX | 36% Loosely correlated | +4.18% | ||
| INCY - VRTX | 34% Loosely correlated | +2.62% | ||
| MRNA - VRTX | 34% Loosely correlated | -1.76% | ||
| MGTX - VRTX | 34% Loosely correlated | +6.75% | ||
More | ||||